Efficacy Trial of a Commercial EV71 Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

15500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-26

Study Completion Date

2020-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-marketing study is to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine post marketing, and explore the protective levels of various enterovirus neutralizing antibodies

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months

NCT03909074

Hand, Foot and Mouth Disease

COMPLETED PHASE3

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine

NCT03865238

Enterovirus 71 Infection

COMPLETED PHASE3

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

NCT05099029

Enterovirus Infections

ACTIVE_NOT_RECRUITING PHASE3

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

NCT03268083

Enterovirus Infections

COMPLETED PHASE2

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

NCT05107557

COVID-19

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a post-marketing aims to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine, and explore the protective levels of various enterovirus neutralizing antibodies. This study includes the following three sections: (1) efficacy study of EV71 vaccine based on enhanced cases monitoring, using prospective cohort study design (2) study on correlation between EV71 vaccine protection and EV71 antibody levels, using case-control study design (3) pathogenic spectrum and sero-epidemiological investigation of hand, foot and mouth disease (HFMD) in children. 15500 volunteers aged 6-71 months are expected to participate in this study, among which 5000 volunteers aged 6-35 months will receive two doses EV71 vaccine manufactured by Sinovac Biotech Co., Ltd, and constitute the experimental cohort. 10000 unvaccinated volunteers aged 6-35 months will constitute the the control cohort. The efficacy evaluation will be conducted based on the abovementioned two cohort. Enhanced HFMD surveillance system will be established to report the HFMD cases in the abovementioned 2 cohorts, as well as another cohort consisting of 500 volunteers aged 36-71 months. The case surveillance period of this study is one year. Laboratory tests will be conducted for case confirmation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hand, Foot and Mouth Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort one

5000 volunteers (6-35 months)-EV71 vaccine

Group Type EXPERIMENTAL

5000 volunteers (6-35 months)-EV71 vaccine

Intervention Type BIOLOGICAL

two doses EV71 vaccines will be administrated on day 0, 30 respectively

Cohort two

10000 unvaccinated volunteers (6-35 months)

Group Type NO_INTERVENTION

No interventions assigned to this group

Cohort three

500 unvaccinated volunteers (36-71 months)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5000 volunteers (6-35 months)-EV71 vaccine

two doses EV71 vaccines will be administrated on day 0, 30 respectively

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteers aged 6-71 months;
* Guardians of the participants voluntarily to vaccinate the participants with EV71 vaccine at their own expense;
* Guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrollment;
* Complying with the requirement of the study protocol;

Exclusion Criteria

* History of HFMD prior to the study entry;
* Prior vaccination with EV71 vaccine;
* History of allergy to any vaccine, or any ingredient, excipients and Gentamycin Sulfate of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc. (only for 6-35 months old subjects of the vaccinated group) ;
* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition (only for 6-35 months old subjects of the vaccinated group);
* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness (only for 6-35 months old subjects of the vaccinated group);
* Autoimmune disease or immunodeficiency/immunosuppressive (only for 6-35 months old subjects of the vaccinated group) ;
* History of asthma, angioedema, diabetes or malignancy (only for 6-35 months old subjects of the vaccinated group);
* Acute disease or acute stage of chronic disease within 7 days prior to study entry (only for 6-35 months old subjects of the vaccinated group);
* Axillary temperature \> 37.0 Celsius (only for 6-35 months old subjects of the vaccinated group)；
* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Minimum Eligible Age

6 Months

Maximum Eligible Age

71 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes